CN1362877A - 用于治疗神经变性的方法 - Google Patents

用于治疗神经变性的方法 Download PDF

Info

Publication number
CN1362877A
CN1362877A CN01800298A CN01800298A CN1362877A CN 1362877 A CN1362877 A CN 1362877A CN 01800298 A CN01800298 A CN 01800298A CN 01800298 A CN01800298 A CN 01800298A CN 1362877 A CN1362877 A CN 1362877A
Authority
CN
China
Prior art keywords
nefiracetam
stroke
patient
treatment
apoplexy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01800298A
Other languages
English (en)
Chinese (zh)
Inventor
大友英一
高须良之
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pharmaceutical Co Ltd
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Publication of CN1362877A publication Critical patent/CN1362877A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CN01800298A 2000-02-23 2001-02-23 用于治疗神经变性的方法 Pending CN1362877A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51195200A 2000-02-23 2000-02-23
US09/511,952 2000-02-23

Publications (1)

Publication Number Publication Date
CN1362877A true CN1362877A (zh) 2002-08-07

Family

ID=24037094

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01800298A Pending CN1362877A (zh) 2000-02-23 2001-02-23 用于治疗神经变性的方法

Country Status (20)

Country Link
US (2) US6423739B1 (enExample)
EP (1) EP1171123B1 (enExample)
JP (1) JP2003523385A (enExample)
KR (1) KR20010110798A (enExample)
CN (1) CN1362877A (enExample)
AR (1) AR030551A1 (enExample)
AT (1) ATE336246T1 (enExample)
AU (1) AU784418B2 (enExample)
BR (1) BR0104586A (enExample)
CA (1) CA2368352C (enExample)
DE (1) DE60122252T2 (enExample)
DK (1) DK1171123T3 (enExample)
ES (1) ES2270981T3 (enExample)
HK (1) HK1047038A1 (enExample)
ID (1) ID30377A (enExample)
IL (1) IL145799A (enExample)
MX (1) MXPA01010749A (enExample)
NO (1) NO321911B1 (enExample)
TW (1) TWI289060B (enExample)
WO (1) WO2001062246A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077709A1 (en) * 1999-05-31 2004-04-22 Daiichi Pharmaceutical Co., Ltd. Neuronal death inhibitors
JPWO2002053153A1 (ja) * 2000-12-28 2004-04-30 第一製薬株式会社 神経因性疼痛治療及び予防薬
CA2457982C (en) * 2001-08-22 2009-11-03 Daiichi Pharmaceutical Co., Ltd. Use of nefiracetam for treating neurodegeneration
RU2205631C1 (ru) * 2002-06-19 2003-06-10 Закрытое акционерное общество "Брынцалов-А" Ноотропное средство "ноотобрил" в форме таблеток
US20060241144A1 (en) * 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome
WO2011048208A1 (en) 2009-10-22 2011-04-28 University College Dublin, National University Of Ireland, Dublin Causal therapy of diseases or conditions associated with cns or pns demyelination
RU2480214C1 (ru) * 2011-09-22 2013-04-27 Валентина Ивановна Ахапкина Состав, обладающий модуляторной активностью с соразмерным влиянием, фармацевтическая субстанция (варианты), применение фармацевтической субстанции, фармацевтическая и парафармацевтическая композиция (варианты), способ получения фармацевтических составов

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2469995A (en) * 1946-07-23 1949-05-10 Schaul Martin Carl Process for the production of food preparations from potatoes and similar farinaceoustubers
US3031314A (en) * 1960-03-16 1962-04-24 Carl E Hendel Preparation of dehydrated potatoes
US3260607A (en) * 1961-02-07 1966-07-12 Canadian Patents Dev Preparation of dehydrated cooked mashed potato
US3968265A (en) * 1973-02-01 1976-07-06 American Potato Company Freeze-thaw stable, french fry potato product and process for producing the same
DE2923975A1 (de) 1979-06-13 1980-12-18 Nattermann A & Cie Pyrrolidinone, verfahren zu deren herstellung und diese enthaltende arzneimittel
IT1141287B (it) 1979-06-13 1986-10-01 Nattermann A & Cie Ammidi di acidi pirrolidin-(2)-on-(1)-ilalchil-carbossilici,procedimento per la loro preparazione e prodotti medicinali che le contengono
DE2924011C2 (de) 1979-06-13 1982-04-08 A. Nattermann & Cie GmbH, 5000 Köln Pyrrolidin-(2)-on-(1)-ylessigsäure-2,6,-dimethylanilid, Verfahren zur Herstellung und Arzneimittel, welche diese Verbindung enthalten
CA2067614C (en) 1991-05-02 2002-07-30 Eiichi Otomo Agent for improving dementia
US5525058A (en) 1992-03-27 1996-06-11 American Dental Technologies, Inc. Dental treatment system
KR100232929B1 (ko) 1995-07-10 1999-12-01 히로지 코데라 가공 선재의 접속 장치
US6107330A (en) 1995-08-07 2000-08-22 Daiichi Pharmaceutical Co., Ltd. Inhibitor for narcotic analgesic dependence/resistance acquisition
JP2002241272A (ja) 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
DK0915658T3 (da) 1996-07-30 2003-02-24 Ecolab Gmbh & Co Ohg Filmdannende middel til beskyttelse mod infektioner
WO1998014213A1 (en) 1996-10-01 1998-04-09 Daiichi Pharmaceutical Co., Ltd. Mitochondrial membrane stabilizer
US6211701B1 (en) 1996-12-16 2001-04-03 Rose Research, Llc Low power line switching circuit, device and method
IT1293533B1 (it) 1997-07-14 1999-03-01 Angeletti P Ist Richerche Bio Metodo per la selezione di molecole in grado di mimare, inibire o potenziare gli effetti della interazione tra leptina e cellule che
US6281242B1 (en) 1997-07-15 2001-08-28 Daiichi Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for amnesia
JPH1180027A (ja) 1997-09-12 1999-03-23 Dai Ichi Seiyaku Co Ltd 向知性薬
TW544311B (en) 1998-08-06 2003-08-01 Daiichi Seiyaku Co Therapeutic or preventive agent for intractable epilepsies
KR20020015321A (ko) 1999-05-31 2002-02-27 스즈키 다다시 신경 세포사 억제제

Also Published As

Publication number Publication date
EP1171123A1 (en) 2002-01-16
AU3414501A (en) 2001-09-03
CA2368352A1 (en) 2001-08-30
IL145799A0 (en) 2002-07-25
ES2270981T3 (es) 2007-04-16
NO20015162D0 (no) 2001-10-22
NO20015162L (no) 2001-12-21
BR0104586A (pt) 2002-01-08
WO2001062246A1 (en) 2001-08-30
US20010051653A1 (en) 2001-12-13
DE60122252D1 (de) 2006-09-28
ID30377A (id) 2001-11-29
DE60122252T2 (de) 2007-07-05
US6423739B1 (en) 2002-07-23
US20020055534A1 (en) 2002-05-09
US6399650B2 (en) 2002-06-04
ATE336246T1 (de) 2006-09-15
KR20010110798A (ko) 2001-12-13
IL145799A (en) 2006-10-31
DK1171123T3 (da) 2006-12-04
HK1047038A1 (zh) 2003-02-07
EP1171123B1 (en) 2006-08-16
AR030551A1 (es) 2003-08-27
TWI289060B (en) 2007-11-01
AU784418B2 (en) 2006-03-30
MXPA01010749A (es) 2002-08-20
NO321911B1 (no) 2006-07-17
JP2003523385A (ja) 2003-08-05
CA2368352C (en) 2009-11-10

Similar Documents

Publication Publication Date Title
RU2221563C2 (ru) Фармацевтическая композиция для лечения болезни паркинсона и синдромов паркинсона, способ ее получения, способ лечения болезни паркинсона и синдромов паркинсона
TWI389689B (zh) 氟利本西林（ｆｌｉｂａｎｓｅｒｉｎ）於治療停經前性慾疾病之用途
WO2006119958A2 (en) Use of flibanserin in the treatment of chronic pain
US20080076820A1 (en) Method for treating neurodegeneration
WO2016184381A1 (zh) 右旋奥拉西坦在制药领域中的应用
JP2021001221A (ja) 精神障害の治療における使用のためのイロペリドン代謝物
CN1362877A (zh) 用于治疗神经变性的方法
US20230089715A1 (en) Masitinib for the treatment of a multiple sclerosis patient subpopulation
CN112770757B (zh) 一种治疗纤维化疾病的药物组合或药物组合物
US5876751A (en) Antispasmodic and antinflammatory composition and a process for the manufacture thereof
WO2020014072A1 (en) Neostigmine pharmaceutical combination for treating myasthenia gravis
NL1018431C2 (nl) EÚnmaal daags farmaceutische samenstelling die brivudine bevat.
EP0868915A1 (en) An anti-spasmodic and antiinflammatory composition containing a NSAID, pentifenone and fenpiverinium
JPWO2004096230A1 (ja) 関節リウマチ治療剤
US20070202503A1 (en) Pharmaceutical Composition Of (+)-Erythro-Mefloquine And Its Use
JPH0436236A (ja) 脳神経障害及び脳循環代謝障害の改善治療剤
KR20080026115A (ko) 1-(3-클로로페닐)-3-알킬파이퍼라진을 포함하는 식욕 이상치료용 약학 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1047038

Country of ref document: HK